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Abstract
Objective To assess whether the prescribing pattern of
lipid-lowering drugs (LLD) changed after reimbursement
criteria revision in a general practice in southern Italy.
Methods From the Caserta-1 Local Health Service data-
base, 93 general practitioners (GPs) who had consistently
sent data about their patients during the years 2003-2005
were recruited. Prevalence of use and incidence of new
treatments were calculated for each year, stratified by three
drug cohorts: statins, omega-3 fatty acids, and fibrates.
Subanalyses by gender, age, and indication of use were
performed.
Results Overall, 1-year prevalence of LLD use increased
from 2003 to 2004. After reimbursement criteria revision
(November 2004), a slight decrease was observed for
statins, from 41.1 (95% CI: 39.9–42.2) per 1,000 inhab-
itants in 2004 to 40.3 (39.2–41.5) in 2005, while omega-3
utilization fell markedly: 14.6 (13.9–15.3) vs. 5.4 (5.0–5.8).
The use of both statins and omega-3 fatty acids was
reduced particularly for primary prevention. On the other
hand, utilization of statins increased in diabetic patients and
as secondary prevention from 2004 to 2005. Concerning
individual molecules, 1-year prevalence of use of any statin
declined from 2004 to 2005, except for rosuvastatin.
Conclusions Revision of reimbursement criteria led to
significant changes in the trend in LLD use in general
practice in southern Italy: (1) statin utilization was slightly
reduced in 2005, although it increased in certain categories,
such as diabetic patients, and (2) omega-3 fatty acid use
was strongly reduced even though a higher use in post-
infarction cases was reported.
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Introduction
Hypercholesterolemia is a well-known risk factor of
cardiovascular (CV) diseases and its successful treatment
with lipid-lowering drugs (LLDs) is one of the most
important goals in CV disease prevention [1].
Utilization of statins has been progressively increasing
worldwide since their marketing in the 1980s, supported by
scientific evidence showing both their effectiveness [2, 3]
and good safety profile [4] in CV disease prevention.
In addition to statins, fibrates and omega-3 polyunsatu-
rated fatty acids are the main LLDs currently marketed.
Omega-3 fatty acids, naturally available in fish, shellfish,
soya oil, leafy vegetables, walnuts, and others, have been
claimed to have a protective role against coronary ischemic
diseases due to lowering of serum triglycerides, platelet
aggregation inhibition, endothelial function modulation,
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blood pressure regulation, and anti-inflammatory and anti-
arrhythmic effects [5].
In Italy omega-3 fatty acids have been marketed since
2001 as prescription drugs totally reimbursed by the
National Health System (NHS), while they are considered
dietetic integrators in other Western countries. As a result,
the consumption of omega-3 fatty acids strongly increased
in Italy, moving from 722nd place in terms of national drug
expenditure in 2001 to 8th in 2004 [6].
In November 2004, the Italian Drug Agency revised
reimbursement criteria of LLDs, as reported in Nota 13 [7],
according to updated scientific evidence.
The aim of this study was to assess whether the trend of
lipid-lowering drug use changed after reimbursement
criteria revision in a general practice in southern Italy. For
this reason, this drug utilization study explored the years
2003–2005.
Methods
Setting
The investigation was carried out using data that were
extracted from the Arianna database in the years 2003–
2005. The database was set up by the Local Health Service
of the city of Caserta in the year 2000. It currently contains
information on almost 300,000 individuals who are living
in the catchment area of Caserta and registered on the lists
of 225 general practitioners (GPs). This sample of
physicians accounts for 74% (225/305) of all the GPs
practicing in the same area. In general, participating GPs
record data during their daily clinical practice through
dedicated software and, monthly, they send complete and
anonymous clinical data about their patients to the Arianna
database. The information collected includes patient demo-
graphics, drug prescriptions (reimbursed by NHS) coded
according to the Anatomical Therapeutic Chemical (ATC)
classification system, and medical diagnoses coded by the
International Classification of Diseases, 9th revision,
Clinical Modification (ICD-9 CM) that are linked to any
drug prescription.
All the GPs enrolled in the Arianna database had
previously received extensive training in data collection
techniques. A number of data quality checks are routinely
performed, including analysis of several variables such as
monthly continuity of data submission, missing patient
codes, and number of prescriptions filled daily. Any
variation beyond the defined range is investigated and the
data are returned to the participating GP in order to receive
immediate feedback about data quality and completeness.
GPs failing to meet these standard quality criteria are not
retained within the analyses, according to basic standards
for the conduct of pharmacoepidemiological studies [8]. So
far, the Arianna database has been shown to provide
accurate and reliable information on drug utilization [9–11].
Study population
Overall, 93 GPs that consistently sent reliable data to the
Arianna database during the years 2003–2005 were selected
for this investigation. Out of the approximately 120,000
individuals registered in their lists, users of LLDs were
identified. LLD users were defined as individuals who
received at least one lipid-modifying agent (ATC: C10)
prescription during the observation years. Patients aged
18 years and over were included in the study, irrespective of
whether LLD treatment was initiated by GPs or by specialists.
Indeed, in Italy outpatients who receive prescriptions from
specialists working in the public or private health-care
services get the medicines free of charge only through GP
prescriptions. After identification of LLD users, the following
information was retrieved using the Arianna database: patient
demographics, LLD-related data, including product name,
dispensed quantity, indication of use, and concurrent diseases
being pharmacologically treated during the years 2003–2005.
Annual utilization of different LLD types was stratified
into primary or secondary prevention. A treatment was
defined as secondary prevention if the LLD user was
affected by coronary heart disease, cerebrovascular disease,
peripheral arterial disease, CV procedures, or diabetes prior
to the first LLD prescription date.
Health policy intervention
LLD reimbursement criteria (Nota 13) were revised in
November 2004. Briefly, the main changes made by this
health-policy intervention are reported below:
1. Omega-3 fatty acids are reimbursed only for treatment
of hyperlipidemia in patients with prior myocardial
infarction (MI), while they had been totally reimbursed
before the revision.
2. Statins are reimbursed in case of hypercholesterolemia
that cannot be corrected through diet only, for both
primary and secondary CV disease prevention.
3. For primary prevention, statin use is now restricted to
high-risk users, based on a national risk profile [12, 13].
For secondary prevention, statin use is reimbursed for
patients affected by coronary heart disease, cerebrovas-
cular disease, peripheral arterial disease, CV procedures
and, after this health policy intervention, the use of statins
was also extended to patients affected by diabetes.
Fibrates, statins, and omega-3 fatty acids are all
reimbursable in case of familial hyperlipidemia (FH), as
indicated also in the previous reimbursement criteria.
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Study drugs
The following drug cohorts were identified:
1. Statins: simvastatin (C10AA01), pravastatin (C10AA03),
fluvastatin (C10AA04), atorvastatin (C10AA05), and
rosuvastatin (C10AA07)
2. Omega-3 fatty acids (C10AX06)
3. Fibrates: clofibrate (C10AB01), bezafibrate (C10AB02),
gemfibrozil (C10AB04), and fenofibrate (C10AB05)
Patients that were treated only with bile acid seques-
trants, nicotinic acid and derivatives, or other lipid-
modifying agents were not taken into account in this
analysis since these drugs are not reimbursed according to
the new health policy intervention.
In addition, lovastatin (C10AA02) and simvastatin-
ezetimibe combination (C10BA02) were not considered
because they were introduced onto the market at the end of
2005 and no prescriptions were filled by physicians within
the observation period.
One-year prevalence and incidence of use
Annual prevalence of LLD treatment was calculated as the
number of LLD users divided by the number of subjects
alive and registered in the GPs’ lists in any study year. We
defined a “new user” as a patient receiving a first LLD
prescription within the observation years without any
recorded LLD prescription in the previous year. The 1-year
cumulative incidence was calculated as the number of new
users divided by the number of subjects who did not take
lipid-lowering drugs in the previous year.
Both prevalence and incidence per year were expressed
as rates per 1,000 inhabitants, together with 95% confi-
dence interval (CI).
Statistical analysis
Two-tailed chi-squared test for proportions and Student’s t-
test for continuous variables, with a significance level of P<
0.05, were used for assessing the differences among users of
various LLD types. Chi-square for trend was used to
evaluate any significant (P<0.05) variation in 1-year
prevalence of LLD use during the study years. Statistical
analyses were performed using STATA 6.0 (STATA, TX).
Results
Prevalence of LLD use
Prevalence of LLD use per 1,000 inhabitants, stratified by
drug types and calendar years, is shown in Fig. 1. The most
commonly used LLDs are statins, which account for more
than 60% of LLD use. Rate of statin users significantly (P<
0.05) increased from 35.3 (34.3–36.4) per 1,000 in 2003 to
41.1 (39.9–41.4) in 2004, while it slightly decreased in the
following year (40.3, 39.2–41.4).
Concerning omega-3 fatty acid use, a significantly
decreased use was reported after reimbursement criteria
revision: from 14.6 (13.9–15.2) per 1,000 in 2004 to 5.4
(5.0–5.8) in 2005. Fibrate use remained consistently low
across the study years, with the lowest rate reported in
2005: 2.2 (2.0–2.5) per 1,000.
No significant differences by gender were reported
among statin users. However, after the health policy
intervention, the prevalence of statin use decreased from
40.1 (38.6–41.7) per 1,000 in 2004 to 37.1 (35.6–38.5) in
2005 among females, while it rose from 42.0 (40.4–43.7) to
43.8 (42.1–45.5) in males in the same period.
With regard to age, prevalence of statin use per year
progressively increased with age during the study period,
while it tended to decrease in patients over 75 years, and, in
particular, over 85 years: 19.7 (14.8–26.3) per 1,000 in
2005 (data not shown).
Omega-3 fatty acid users were significantly younger
(mean age ± SD: 59.8±13.3 years) than statin users (63.8±
11.7 years). After the health policy intervention, however, a
strong reduction in omega-3 fatty acid use was reported in
all age groups (data not shown).
Among statin users, a subanalysis was performed to
assess the annual prevalence of use of individual molecules
(Fig. 2). Atorvastatin was the most used statin in each study
year [in 2005: 16.3 (15.6–17.1) per 1,000], followed by
simvastatin and pravastatin. One-year prevalence of use of
all statins decreased from 2004 to 2005, except for
rosuvastatin, which increased from 3.7 (3.4–4.1) to 6.1
(5.6–6.4).
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Fig. 1 Prevalence of lipid-lowering drug use per 1,000 inhabitants,
stratified by drug type and calendar year
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Differences by drug type were highlighted after analyz-
ing the prevalence of use per year, according to indication
of use (Fig. 3).
Statin utilization for primary prevention was slightly
reduced after reimbursement criteria revision [in 2004: 31.2
(30.2–32.2); in 2005: 27.8 (26.9–28.8)], while a much
stronger reduction was reported for omega-3 fatty acid use:
from 11.2 (10.6–11.8) in 2004 to 3.8 (3.4–4.1) in 2005.
On the other hand, the rate of statin prescriptions for
secondary prevention rose consistently during the study
years: from 6.8 (6.3–7.2) per 1,000 in 2003 up to 12.5
(11.9–13.1) in 2005. In particular, the 1-year prevalence of
statin use in patients with diabetes progressively increased
from 3.1 (2.8–3.5) in 2003 to 6.9 (6.4–7.4) in 2005 (data
not shown).
In contrast, omega-3 fatty acid use for secondary
prevention decreased from 2004 (3.4; 3.1–3.7) to 2005
(1.6; 1.4–1.9). After the health policy intervention, patients
affected by myocardial infarction accounted for the major-
ity of users.
Utilization of fibrates remained very low for both
primary and secondary prevention compared to other LLDs
during the study years.
One-year incidence of LLD use
A significant decrease in annual incidence of LLD
treatment was observed from 2004 to 2005 for all drug
classes (Fig. 4). However, a highly significant reduction in
1-year incidence was reported only for omega-3 fatty acid
users, falling from 5.4 (4.9–5.8) per 1,000 inhabitants in
2004 to 0.9 (0.7–1.1) in 2005.
Incident treatments with statins (in 2005: 10.1; 9.5–10.7)
remained remarkably higher than other LLDs.
Discussion
In November 2004, the Italian Drug Agency revised LLD
reimbursement criteria (Nota 13) in light of updated
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Fig. 3 Prevalence of LLD use per 1,000 inhabitants during the study
years, stratified by drug type and indication of use. PP Primary
prevention, SP secondary prevention. Secondary prevention was
defined as treatment of patients with well-documented coronaropathy,
prior stroke, prior myocardial infarction, peripheral obliterative
arteriopathy or diabetes
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Fig. 4 One-year incidence (per 1,000 inhabitants) of treatment with
LLD for the years 2003–2005, stratified by drug type
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scientific evidence [7]. The results of our study highlight
that the health policy intervention significantly influenced
statin and omega-3 fatty acid use in a general practice in
southern Italy.
Concerning statins, a peculiar trend was reported in our
analysis: the prevalence of statin use per year increased
from 2003 to 2004, while it slightly decreased in 2005 after
reimbursement criteria revision. The increase in statin use
from 2003 to 2004 is in line with previous investigations
that found a constantly growing use of statins in most
European countries since their marketing began [14]. In
particular, a previous study that explored statin utilization in
northern Italy over a 10-year period (1994–2003) reported a
28% average increase per year [15]. On the other hand, the
reimbursement criteria revision led to a slight reduction in
both 1-year prevalence and incidence of statin use with a
different prescribing pattern of these LLDs.
This could be explained by the fact that statin prescrip-
tions are currently reimbursed for primary prevention
according to new cardiovascular risk charts [12]. These
risk charts lead to a reduction in statin use as primary
prevention since the absolute risk in the Italian population
is lower than in the U.S. population. Moreover, this
reduction mainly relates to women on the basis of scientific
evidence supporting that cardiovascular risk factors affect
more men than women [16, 17].
The health policy intervention did not determine any
significant change in the statin use by age groups, although
the time window of the study may have been too short to
adequately evaluate it. In all study years, prevalence of use
of these LLDs decreased in patients over 75 and,
particularly, over 85 years. In line with our results, a
British study [18] highlighted that statin use in very old
patients is strikingly lower compared to younger patients
and, in some cases, the elderly who could benefit from LLD
treatment do not receive it. An animated debate is currently
underway within the scientific community about the
appropriateness of LLD treatment in older patients [19].
Some clinical trials have shown the benefits of statin
therapy in cardiovascular prevention also in elderly with
hypercholesterolemia [20].
Interestingly, statins were more prescribed for primary
than for secondary prevention in all the study years. After
reimbursement criteria, however, their use rose in patients
for secondary prevention and, in particular, in patients
affected by diabetes mellitus. Indeed, patients with hyper-
cholesterolemia can be treated with statins free of charge in
case of secondary prevention, including diabetes mellitus,
after the health policy intervention.
The revision of reimbursement criteria was based on recent
scientific evidence showing a significant reduction in risk of
vascular events in diabetic patients who are treated with statins
for both primary and secondary prevention [21, 22].
Looking at individual molecules, atorvastatin and sim-
vastatin were the most used statins during the study years,
in line with a previous European investigation [14] and the
Italian national report [6]. In our investigation, however, the
annual prevalence of use of any statin was reduced after
reimbursement criteria revision, with the exception of
rosuvastatin, which was first marketed in Italy in 2004.
The extensive marketing campaign launched by the drug
manufacturer to promote this statin could partly explain the
unusual increase [23]. This finding confirms the trend of
newly marketed drugs to be widely prescribed in general
practice immediately after their introduction to the drug
market, despite a proven lack of effectiveness and safety
data derived from clinical practice [24].
The effect of the reimbursement criteria revision on
omega-3 fatty acids was a dramatic reduction, in particular
of new treatments, from 2004 to 2005. Our results are in
line with an Italian national report that reported a 40%
decrease in omega-3 fatty acid use in 2005 compared to the
previous year [6]. This finding might be explained by the
restriction in reimbursement criteria of omega-3 fatty acids,
which are now free of charge only in patients with a history
of myocardial infarction. It should be emphasized that
omega-3 prescriptions had been totally reimbursed for
primary prevention prior to reimbursement criteria revision,
although clinical trials [25] that showed omega-3 fatty acid
benefits in CV prevention had included only patients with a
recent history of myocardial infarction.
Compared to statins and omega-3 fatty acids, use of
fibrates was remarkably low during the observation years.
Such a finding is in contrast with other European countries
where these LLDs account for almost one-fourth of total
LLD utilization [14]. We were not able to accurately
characterise the users of fibrates in light of the low
utilization of these LLDs.
Overall it seems that the health policy intervention led to
changes in LLD prescribing patterns that are in line with
Europan recommendations for pharmacological treatment
of lipid disorders [26]. On the other hand, a Belgian
investigation [27] that analyzed the impact of health policy
intervention on statin utilization for secondary prevention
highlighted that reimbursement criteria restriction of LLD
could also lead to underutilization in patients who would
have benefited from LLD therapy.
Strengths and limitations of the study
To our knowledge, this is the first drug-utilization study
targeted to measure the prevalence of LLD use as both
primary and secondary prevention in a general practice in
southern Italy. In particular, the availability of prescription
data from 2003 to 2005 allowed us to evaluate the effect of
reimbursement criteria revision on LLD use in clinical
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practice. Moreover, we were also able to evaluate some
clinically relevant characteristics of LLD users, such as
indication of use.
However, several limitations of our study warrant
caution. First of all, we used outpatient prescription data,
and we had no information whether LLD prescriptions were
actually filled and taken. This limit should be taken into
account since around half of the medicines prescribed for
people with chronic conditions are not ultimately taken
[28]. Nevertheless, our study was aimed at evaluating how
the GPs’ prescribing behavior was influenced by the health
policy intervention. Therefore, this prescription database
can be considered suitable for such an investigation.
Second, we could not evaluate the number of LLD
prescriptions that were not reimbursed by the National
Health System. Data from an Italian national report on drug
consumption, however, showed a strong decrease in
omega-3 fatty acid use after reimbursement criteria revi-
sion, thus supporting one of the main findings of our study
[29]. Furthermore, we did not take into account familial
dyslipidemia as a potential indication of LLD use, even
though all LLD treatments are fully reimbursed in such a
condition. Indeed, this diagnosis is not accurately codified
through ICD-9 codes in general practice, but a previous
Italian investigation [30] reported only 13% of statin
prescriptions are filled to patients with familial dyslipidemia.
In conclusion, the health policy intervention modified
the trend in the lipid-lowering drug use in general practice.
Statin utilization was slightly reduced in 2005, although it
increased in certain categories of patients (diabetes mellitus
and secondary prevention). Conversely, omega-3 fatty acid
utilization was markedly reduced in 2005.
In the management of dyslipidemia and cardiovascular
prevention, the appropriateness of GP prescribing could be
improved through reimbursement criteria revisions based
on updated scientific evidence. A definition of these
criteria, however, should be developed among regulatory
agencies and health professionals.
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